Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03900793 · ClinicalTrials.gov registry record · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
A Phase 1 study of Osteosarcoma, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 4
- Study locations
NCT03900793: Recruiting Phase 1 study of Osteosarcoma, sponsored by University of Colorado, Denver.
NCT03900793 is a Phase 1 study of Osteosarcoma that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 41 participants, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03900793, a Phase 1 study of Osteosarcoma, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is a Phase 1/1b clinical trial that aims to determine the Maximally Tolerated Dose of Losartan and Sunitinib Combination Therapy. Patients will first be accrued to the Dose Escalation phase of the study, using a 3+3 design. Medication dosages will increase until a maximally tolerated dose is found. Patients will then be accrued to the Dose Expansion phase of the trial, where efficacy of pre-determined dose will be preliminarily assessed.
Primary Outcome
Assessment of Dose-Limiting Toxicities (DLTs) according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5 to assess the safety of the combination
Conditions Studied
Interventions
- DRUG Sunitinib
- DRUG Losartan
Study Locations (4)
Colorado
- Children's Hospital Colorado - Aurora
- University of Colorado Hospital - Aurora
California
- Children's Hospital Los Angeles - Los Angeles
Georgia
- Children's Hospital of Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
What NCT03900793 shows while recruiting
NCT03900793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Osteosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Sunitinib is the first listed.
NCT03900793 reports a single indexed study location in Colorado, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT03900793 about?
NCT03900793 is a clinical study titled "Losartan + Sunitinib in Treatment of Osteosarcoma". This study is a Phase 1/1b clinical trial that aims to determine the Maximally Tolerated Dose of Losartan and Sunitinib Combination Therapy. Patients will first be accrued to the Dose Escalation phase of the study, using a 3+3 design. Medication dosages will increase until a maximally tolerated dose...
What is the current status of trial NCT03900793?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2019-08-26. Estimated completion is 2027-02.
What conditions does trial NCT03900793 study?
This clinical trial studies the following conditions: Osteosarcoma.
What interventions are being tested in trial NCT03900793?
The interventions under investigation include: Sunitinib (DRUG), Losartan (DRUG).
Who is sponsoring clinical trial NCT03900793?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03900793 being conducted?
This trial has 4 study locations across California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03900793's enrollment target sits among peer trials
41 25th of 46 higher than 21 of 46 other Osteosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
- NCT04240054 · 41 participants · Phase 2
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI